Distinguished in Richter Syndrome

Dr. Abdulraheem M. Yacoub

Hematology
4350 Shawnee Mission Parkway, 
Fairway, KS 
Accepting New Patients
Offers Telehealth
Distinguished in Richter Syndrome
4350 Shawnee Mission Parkway, 
Fairway, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abdulraheem Yacoub is a Hematologist in Fairway, Kansas. Dr. Yacoub is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is currently accepting new patients.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Student in an Organized Health Care Education/Training Program in MO
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

The University of Kansas Health System - Clinical Research Center
4350 Shawnee Mission Parkway, Fairway, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

60 Total Publications

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 08, 2025
Similar Doctors
Distinguished in Richter Syndrome
Dr. Larry R. Corum
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Larry R. Corum
Hematology Oncology | Hematology | Oncology

Kansas University Physicians Inc

20333 W 151st St, Olathe Medical Center, 
Olathe, KS 
 (16.7 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Larry Corum is a Hematologist Oncology specialist and a Hematologist in Olathe, Kansas. Dr. Corum is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), and Lung Cancer. Dr. Corum is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Marc S. Hoffmann
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Marc S. Hoffmann
Hematology Oncology | Hematology | Oncology

Select Physical Therapy Holdings Inc

2301 S Missouri 291 Hwy, 
Independence, MO 
 (13.1 miles away)
816-373-9328
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Hoffmann is a Hematologist Oncology specialist and a Hematologist in Independence, Missouri. Dr. Hoffmann is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Hoffmann is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Joseph F. Stilwill
Hematology Oncology | Hospital Medicine | Hematology
Distinguished in Richter Syndrome
Dr. Joseph F. Stilwill
Hematology Oncology | Hospital Medicine | Hematology

Midwest Oncology Associates LLC

10500 Quivira Rd, 
Overland Park, KS 
 (8.9 miles away)
913-541-5372
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Stilwill is a Hematologist Oncology specialist and a Hospital Medicine provider in Overland Park, Kansas. Dr. Stilwill is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Mantle Cell Lymphoma (MCL), Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Stilwill is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yacoub's expertise for a condition
ConditionClose
View All 23 Distinguished Conditions
View All 25 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile